{"id":"drug-shr0302","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, SHR0302 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.","oneSentence":"SHR0302 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:35:30.688Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04333771","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-07-31","conditions":"Rheumatoid Arthritis","enrollment":566},{"nctId":"NCT04717310","phase":"PHASE2, PHASE3","title":"Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis","status":"UNKNOWN","sponsor":"Reistone Biopharma Company Limited","startDate":"2020-12-30","conditions":"Atopic Dermatitis","enrollment":645},{"nctId":"NCT05470413","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata","status":"UNKNOWN","sponsor":"Reistone Biopharma Company Limited","startDate":"2022-04-18","conditions":"Alopecia Areata","enrollment":330},{"nctId":"NCT05136456","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy","status":"UNKNOWN","sponsor":"Reistone Biopharma Company Limited","startDate":"2021-12-15","conditions":"Primary Membranous Nephropathy","enrollment":61},{"nctId":"NCT03675477","phase":"PHASE2","title":"A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.","status":"COMPLETED","sponsor":"Reistone Biopharma Company Limited","startDate":"2019-04-13","conditions":"Ulcerative Colitis","enrollment":164},{"nctId":"NCT04875169","phase":"PHASE3","title":"Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Reistone Biopharma Company Limited","startDate":"2021-04-30","conditions":"Atopic Dermatitis","enrollment":336},{"nctId":"NCT04162899","phase":"PHASE2","title":"A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Reistone Biopharma Company Limited","startDate":"2019-11-06","conditions":"Atopic Dermatitis","enrollment":105},{"nctId":"NCT03677648","phase":"PHASE2","title":"A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease","status":"COMPLETED","sponsor":"Reistone Biopharma Company Limited","startDate":"2019-05-14","conditions":"Crohn's Disease","enrollment":112},{"nctId":"NCT05392127","phase":"PHASE1","title":"A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-07-15","conditions":"Rheumatoid Arthritis","enrollment":24},{"nctId":"NCT04774809","phase":"PHASE2, PHASE3","title":"Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo","status":"TERMINATED","sponsor":"Reistone Biopharma Company Limited","startDate":"2020-01-29","conditions":"Vitiligo","enrollment":75},{"nctId":"NCT02665910","phase":"PHASE1","title":"Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2016-05","conditions":"Rheumatoid Arthritis","enrollment":48},{"nctId":"NCT02423538","phase":"PHASE1","title":"First-in-Human Single Ascending Dose of SHR0302","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-04","conditions":"Rheumatoid Arthritis","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Drug: SHR0302","genericName":"Drug: SHR0302","companyName":"Reistone Biopharma Company Limited","companyId":"reistone-biopharma-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR0302 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}